NZ595691A - Drug delivery composition - Google Patents

Drug delivery composition

Info

Publication number
NZ595691A
NZ595691A NZ595691A NZ59569110A NZ595691A NZ 595691 A NZ595691 A NZ 595691A NZ 595691 A NZ595691 A NZ 595691A NZ 59569110 A NZ59569110 A NZ 59569110A NZ 595691 A NZ595691 A NZ 595691A
Authority
NZ
New Zealand
Prior art keywords
coating
group
medicament
particles
surface stabilizer
Prior art date
Application number
NZ595691A
Inventor
Stephen B Ruddy
Simon L Mcgurk
Rakesh Patel
John Bullock
Raj Kewalramani
Original Assignee
Alkermes Pharma Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alkermes Pharma Ireland Ltd filed Critical Alkermes Pharma Ireland Ltd
Publication of NZ595691A publication Critical patent/NZ595691A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Disclosed is a composition comprising: a semipermeable coating; particles of a medicament having an effective average particle size of less than or about 2 um (micrometres) and a surface stabilizer adsorbed on the surface of the medicament particles; and a solubilizing agent. Semi-permeable coatings can be selected from the group consisting of a controlled-porosity microporous coating, a water swellable coating. Surface stabilizer is selected from the group consisting of hydroxypropyl methylcellulose (HPMC), dioctyl sodium sulfosuccinate (DOSS), sodium lauryl sulfate (SLS), hydroxypropyl cellulose, polyvinylpyrrolidone, sodium deoxycholate, block copolymers based on ethylene oxide and propylene oxide, copolymers of vinylpyrrolidone and vinyl acetate, lecithin, polyoxyethylene sorbitan fatty acid esters, albumin, lysozyme, gelatin, macrogol 15 hydroxystearate, tyloxapol, and polyethoxylated castor oil.
NZ595691A 2009-04-09 2010-04-08 Drug delivery composition NZ595691A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16804009P 2009-04-09 2009-04-09
PCT/US2010/030387 WO2010118228A1 (en) 2009-04-09 2010-04-08 Drug delivery composition

Publications (1)

Publication Number Publication Date
NZ595691A true NZ595691A (en) 2013-06-28

Family

ID=42934579

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ595691A NZ595691A (en) 2009-04-09 2010-04-08 Drug delivery composition

Country Status (15)

Country Link
US (3) US20100260858A1 (en)
EP (2) EP2416782A1 (en)
JP (4) JP2012523427A (en)
KR (1) KR20120022895A (en)
CN (2) CN102448447A (en)
AU (2) AU2010234339B2 (en)
BR (2) BRPI1010511A2 (en)
CA (2) CA2758258A1 (en)
IL (1) IL215608A0 (en)
MX (2) MX2011010621A (en)
NZ (1) NZ595691A (en)
RU (3) RU2589823C2 (en)
SG (1) SG175137A1 (en)
TW (2) TWI546088B (en)
WO (2) WO2010118228A1 (en)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100260858A1 (en) * 2009-04-09 2010-10-14 Elan Pharma International Limited Drug delivery composition
EP2424581B1 (en) 2009-04-28 2017-03-01 SurModics, Inc. Devices and methods for delivery of bioactive agents
CA2786819A1 (en) 2010-01-13 2011-07-21 Jazz Pharmaceuticals Plc Method for titrating clozapine
WO2011146583A2 (en) 2010-05-19 2011-11-24 Elan Pharma International Limited Nanoparticulate cinacalcet formulations
US10010514B2 (en) * 2010-07-08 2018-07-03 Wellesley Pharmaceuticals, Llc Pharmaceutical formulation for reducing frequency of urination and method of use thereof
US9861727B2 (en) 2011-05-20 2018-01-09 Surmodics, Inc. Delivery of hydrophobic active agent particles
US9757497B2 (en) * 2011-05-20 2017-09-12 Surmodics, Inc. Delivery of coated hydrophobic active agent particles
US10213529B2 (en) * 2011-05-20 2019-02-26 Surmodics, Inc. Delivery of coated hydrophobic active agent particles
CN104853749A (en) * 2012-09-17 2015-08-19 塔瑞克斯制药有限公司 Oral formulations of angiotensin
JP6438406B2 (en) 2012-11-05 2018-12-12 サーモディクス，インコーポレイテッド Compositions and methods for delivering hydrophobic bioactive agents
US11246963B2 (en) 2012-11-05 2022-02-15 Surmodics, Inc. Compositions and methods for delivery of hydrophobic active agents
EP2968359B1 (en) * 2013-03-12 2021-01-20 Celltaxis, LLC Methods of inhibiting leukotriene a4 hydrolase
EP2968264A4 (en) 2013-03-14 2016-11-02 Celtaxsys Inc Inhibitors of leukotriene a4 hydrolase
TW201503912A (en) * 2013-03-19 2015-02-01 Novartis Ag Pharmaceutical compositions comprising everolimus
AU2014306759B2 (en) 2013-08-12 2018-04-26 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
WO2015095391A1 (en) 2013-12-17 2015-06-25 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
EP3169315B1 (en) 2014-07-17 2020-06-24 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
US20160106737A1 (en) 2014-10-20 2016-04-21 Pharmaceutical Manufacturing Research Services, Inc. Extended Release Abuse Deterrent Liquid Fill Dosage Form
KR102274297B1 (en) * 2014-11-06 2021-07-07 주식회사 엘지생활건강 Cosmetic composition containing octylgallate
WO2016185443A1 (en) 2015-05-20 2016-11-24 Novartis Ag Pharmaceutical combination of everolimus with dactolisib
KR101884230B1 (en) * 2016-02-29 2018-08-01 주식회사 유영제약 Formulation containing esomeprazole
SG11201811351WA (en) * 2016-07-05 2019-01-30 Timilon Tech Acquisitions Llc Compositions and methods for forming stable, liquid metal oxide/hydroxide formulations
ES2960331T3 (en) * 2016-09-17 2024-03-04 Intas Pharmaceuticals Ltd Clozapine Extended Release Pharmaceutical Composition
US11534404B2 (en) * 2016-10-06 2022-12-27 Sucampo Ag Multilayer beads for pharmaceutical use
BR112019010470A2 (en) 2016-11-23 2019-09-10 Novartis Ag immune response enhancement methods with everolimus, dactolisib or both
US10898446B2 (en) 2016-12-20 2021-01-26 Surmodics, Inc. Delivery of hydrophobic active agents from hydrophilic polyether block amide copolymer surfaces
US11534397B2 (en) * 2017-11-09 2022-12-27 The Board Of Regents Of The University Of Oklahoma Nanocrystal microparticles of poorly soluble drugs and methods of production and use thereof
US10596165B2 (en) 2018-02-12 2020-03-24 resTORbio, Inc. Combination therapies
CN108371728B (en) * 2018-03-09 2020-12-18 西南交通大学 Preparation method of mussel-like contact antibacterial hydrogel for tissue repair
CN108295264A (en) * 2018-03-28 2018-07-20 五邑大学 The application of polyvinylpyrrolidone k12
US11672781B2 (en) 2018-05-07 2023-06-13 Prana Biosciences Inc Metaxalone formulations
AU2019278935A1 (en) 2018-05-31 2020-12-10 Celltaxis, Llc Method of reducing pulmonary exacerbations in respiratory disease patients
CN109602952B (en) * 2018-12-27 2021-05-18 上海北陆医药科技有限公司 Long-acting slow-release cell scaffold and preparation method and application thereof
US11918590B2 (en) * 2021-12-15 2024-03-05 Intas Pharmaceuticals Ltd. Stable extended release pharmaceutical composition of clozapine

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3173876A (en) * 1960-05-27 1965-03-16 John C Zobrist Cleaning methods and compositions
NL271831A (en) * 1960-11-29
US3276586A (en) * 1963-08-30 1966-10-04 Rosaen Filter Co Indicating means for fluid filters
US3546142A (en) * 1967-01-19 1970-12-08 Amicon Corp Polyelectrolyte structures
DE1720701A1 (en) * 1967-08-22 1971-07-15 Bayer Ag Crosslinkable lacquer resins
FR2000803A1 (en) * 1968-01-26 1969-09-12 Kalle Ag
US3541006A (en) * 1968-07-03 1970-11-17 Amicon Corp Ultrafiltration process
US3615024A (en) * 1968-08-26 1971-10-26 Amicon Corp High flow membrane
BE758820A (en) * 1969-11-13 1971-05-12 Celanese Corp PROCESS FOR THE PRODUCTION OF OPEN-CELL MICROPOROUS FILMS
FR2105306A5 (en) * 1970-08-07 1972-04-28 Rhone Poulenc Sa
CA984567A (en) * 1972-02-16 1976-03-02 Albert E. Smith Microporous polymer sheets
US3852224A (en) * 1972-09-14 1974-12-03 Tee Pak Inc Microporous films
US4014334A (en) * 1976-02-02 1977-03-29 Alza Corporation Laminated osmotic system for dispensing beneficial agent
DE3000979A1 (en) * 1980-01-12 1981-07-23 Dr. Karl Thomae Gmbh, 7950 Biberach NEW DIPYRIDAMOL RETARD FORMS AND METHOD FOR THEIR PRODUCTION
US4576604A (en) * 1983-03-04 1986-03-18 Alza Corporation Osmotic system with instant drug availability
US4624847A (en) * 1985-04-22 1986-11-25 Alza Corporation Drug delivery device for programmed delivery of beneficial drug
US4971790A (en) * 1986-02-07 1990-11-20 Alza Corporation Dosage form for lessening irritation of mocusa
US4801461A (en) * 1987-01-28 1989-01-31 Alza Corporation Pseudoephedrine dosage form
GB8717168D0 (en) * 1987-07-21 1987-08-26 Roussel Lab Ltd Controlled-release device
US4946686A (en) * 1987-09-24 1990-08-07 Merck & Co., Inc. Solubility modulated drug delivery system
US5324280A (en) * 1990-04-02 1994-06-28 Alza Corporation Osmotic dosage system for delivering a formulation comprising liquid carrier and drug
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5260068A (en) * 1992-05-04 1993-11-09 Anda Sr Pharmaceuticals Inc. Multiparticulate pulsatile drug delivery system
DK0621032T3 (en) * 1993-04-23 2000-10-23 Novartis Ag Medicinal product with controlled release
US5558879A (en) * 1995-04-28 1996-09-24 Andrx Pharmaceuticals, Inc. Controlled release formulation for water soluble drugs in which a passageway is formed in situ
DE69709646T2 (en) * 1996-03-12 2002-08-14 Alza Corp COMPOSITION AND DOSAGE WITH AN OPIOID ANTAGONIST
DE19635676A1 (en) * 1996-09-03 1998-03-05 Basf Ag Solid foamed active ingredient preparations
US6110498A (en) * 1996-10-25 2000-08-29 Shire Laboratories, Inc. Osmotic drug delivery system
US5788987A (en) * 1997-01-29 1998-08-04 Poli Industria Chimica Spa Methods for treating early morning pathologies
US6045829A (en) * 1997-02-13 2000-04-04 Elan Pharma International Limited Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
AU1534699A (en) * 1997-12-05 1999-06-28 Alza Corporation Osmotic dosage form comprising first and second coats
WO1999034751A1 (en) * 1998-01-06 1999-07-15 Sceusa Nicholas A A drug dosage form based on the teorell-meyer gradient
US6004584A (en) * 1998-03-02 1999-12-21 The Procter & Gamble Company Highly absorbent body powders
WO2000018374A1 (en) * 1998-10-01 2000-04-06 Elan Pharma International, Ltd. Controlled release nanoparticulate compositions
DK1126826T6 (en) * 1998-11-02 2019-06-24 Alkermes Pharma Ireland Ltd Multiparticulate modified release of methylphenidate
ATE260642T1 (en) * 1998-12-17 2004-03-15 Alza Corp CONVERSION OF LIQUID-FILLED GELATIN CAPSULES INTO SYSTEMS WITH CONTROLLED ACTIVE RELEASE THROUGH MULTIPLE COATINGS
US6267989B1 (en) * 1999-03-08 2001-07-31 Klan Pharma International Ltd. Methods for preventing crystal growth and particle aggregation in nanoparticulate compositions
JP2003513033A (en) * 1999-10-29 2003-04-08 メルク エンド カムパニー インコーポレーテッド Osmotic controlled release drug delivery device
US20030180352A1 (en) * 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
EP1269994A3 (en) * 2001-06-22 2003-02-12 Pfizer Products Inc. Pharmaceutical compositions comprising drug and concentration-enhancing polymers
US20030068356A1 (en) * 2001-07-10 2003-04-10 Pather S. Indiran Sequential drug delivery systems
US8329217B2 (en) * 2001-11-06 2012-12-11 Osmotica Kereskedelmi Es Szolgaltato Kft Dual controlled release dosage form
TW200302748A (en) * 2002-02-01 2003-08-16 Pfizer Prod Inc Osmotic delivery system
AU2003234452A1 (en) * 2002-05-06 2003-11-11 Elan Pharma International Ltd. Nanoparticulate nystatin formulations
US20080220074A1 (en) * 2002-10-04 2008-09-11 Elan Corporation Plc Gamma radiation sterilized nanoparticulate docetaxel compositions and methods of making same
US7611728B2 (en) * 2003-09-05 2009-11-03 Supernus Pharmaceuticals, Inc. Osmotic delivery of therapeutic compounds by solubility enhancement
WO2005063206A1 (en) * 2003-12-23 2005-07-14 Alza Corporation Methods and dosage forms for increasing solubility of drug compositions for controlled delivery
US20050196446A1 (en) * 2004-03-05 2005-09-08 Huang Hai Y. Polymeric compositions and dosage forms comprising the same
US7728015B2 (en) * 2004-04-22 2010-06-01 Mor Research Applications Ltd. Compositions for weight management
JP2008524239A (en) * 2004-12-15 2008-07-10 エラン ファーマ インターナショナル リミティド Nanoparticulate tacrolimus formulation
CN101132768A (en) * 2004-12-15 2008-02-27 伊兰制药国际有限公司 Nanoparticulate tacrolimus formulations
US20080254114A1 (en) * 2005-03-03 2008-10-16 Elan Corporation Plc Controlled Release Compositions Comprising Heterocyclic Amide Derivative Nanoparticles
WO2007022501A2 (en) * 2005-08-18 2007-02-22 Microbia, Inc. Useful indole compounds
EA017290B1 (en) * 2005-11-28 2012-11-30 Домейн Раша Инвестментс Лимитед Ganaxolone-based formulations
EP1976492B8 (en) * 2006-01-27 2018-07-04 Adare Pharmaceuticals, Inc. Drug delivery systems comprising weakly basic drugs and organic acids
ES2531215T3 (en) * 2006-01-27 2015-03-11 Aptalis Pharmatech Inc Drug delivery systems comprising a weakly basic serotonin 5-HT3 selective blocking agent and organic acids
CA2661683C (en) * 2006-08-31 2015-11-24 Eurand, Inc Drug delivery systems comprising solid solutions of weakly basic drugs
US20090004281A1 (en) * 2007-06-26 2009-01-01 Biovail Laboratories International S.R.L. Multiparticulate osmotic delivery system
US8133506B2 (en) * 2008-03-12 2012-03-13 Aptalis Pharmatech, Inc. Drug delivery systems comprising weakly basic drugs and organic acids
TWI519322B (en) * 2008-04-15 2016-02-01 愛戴爾製藥股份有限公司 Compositions comprising weakly basic drugs and controlled-release dosage forms
RU2403041C2 (en) * 2008-12-18 2010-11-10 Автономная некоммерческая организация "Институт молекулярной диагностики" (АНО "ИнМоДи") D-cycloserin-based medication of plolonged action with dosed release in target organs for treatment of resistant forms of tuberculosis
US20100260858A1 (en) * 2009-04-09 2010-10-14 Elan Pharma International Limited Drug delivery composition

Also Published As

Publication number Publication date
JP2015007111A (en) 2015-01-15
US20100260858A1 (en) 2010-10-14
EP2416764A1 (en) 2012-02-15
EP2416764A4 (en) 2013-09-04
CA2758258A1 (en) 2010-10-14
TW201039867A (en) 2010-11-16
MX2011010621A (en) 2012-01-30
CN102448447A (en) 2012-05-09
RU2011145278A (en) 2013-05-20
AU2010234339A1 (en) 2011-11-10
AU2010234339B2 (en) 2014-06-26
SG175137A1 (en) 2011-11-28
JP2012523427A (en) 2012-10-04
RU2011145279A (en) 2013-05-20
IL215608A0 (en) 2011-12-29
RU2016120727A (en) 2018-11-12
CA2757979A1 (en) 2010-10-14
BRPI1010301A2 (en) 2016-03-15
TWI546088B (en) 2016-08-21
JP5934312B2 (en) 2016-06-15
WO2010118232A1 (en) 2010-10-14
JP2016138136A (en) 2016-08-04
MX2011010620A (en) 2012-01-20
US20150283092A1 (en) 2015-10-08
TW201039864A (en) 2010-11-16
CN105581984A (en) 2016-05-18
KR20120022895A (en) 2012-03-12
RU2589823C2 (en) 2016-07-10
BRPI1010511A2 (en) 2019-04-09
AU2010234343A1 (en) 2011-11-24
WO2010118228A1 (en) 2010-10-14
EP2416782A1 (en) 2012-02-15
US20100260859A1 (en) 2010-10-14
JP2012523428A (en) 2012-10-04

Similar Documents

Publication Publication Date Title
NZ595691A (en) Drug delivery composition
ES2189232T5 (en) Gastrically protected omeprazole microgranules, procedure for obtaining and pharmaceutical preparations
EA033370B1 (en) Formulations of rifaximin and uses thereof
HRP20151357T1 (en) The use of solid carrier particles to improve the processability of a pharmaceutical agent
KR20100014629A (en) Modified dosage forms of tacrolimus
UA102885C2 (en) Pharmaceutical composition for oral administration
JP5524624B2 (en) Aqueous film coating solution, film coated granule, and tablet using the same
JP2014208655A5 (en)
WO2012075015A2 (en) Oral metronidazole pharmaceutical compositions
IL260229B2 (en) St-246 (tecovirimat monohydrate) suspension formulations
MX2013000284A (en) Orally disintegrating tablet.
US20080069870A1 (en) Controlled Release Compositions Comprising a Cephalosporin for the Treatment of a Bacterial Infection
WO2012020301A3 (en) Oral controlled release pharmaceutical compositions of blonanserin
WO2011045774A2 (en) Extended release pharmaceutical compositions of paliperidone and processes of preparation thereof
WO2018229784A1 (en) Pharmaceutical compositions of dabigatran
US20100209500A1 (en) Controlled release budesonide minitablets
JP4771956B2 (en) Composition of a quaternary ammonium compound containing a bioavailability enhancer
TW201332591A (en) Pharmaceutical composition for the prolonged release of trimetazidine
US8945616B2 (en) Controlled release budesonide minitablets
AU2006209212B2 (en) Controlled release compositions comprising an antipsychotic agent
PH12014502609B1 (en) Multilayer coating form of orally administered pharmaceutical composition containing omega-3 fatty acid or alkyl ester thereof and statin based drug
WO2011080570A8 (en) Extended release pharmaceutical composition comprising linezolid and process for preparing the same
JP2016504390A5 (en)
CA2433915A1 (en) Improved controlled release oral dosage form
EP3848037A1 (en) Solid pharmaceutical composition containing 1,3,5-triazine derivative or salt thereof

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 08 APR 2017 BY COMPUTER PACKAGES INC

Effective date: 20140429

LAPS Patent lapsed